Log In
BCIQ
Print this Print this
 

BI 655064

  Manage Alerts
Collapse Summary General Information
Company Boehringer Ingelheim GmbH
DescriptionAnti-CD40 mAb
Molecular Target CD40
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationLupus
Indication DetailsTreat lupus nephritis
Regulatory Designation
PartnerAbbVie Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$595.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/07/2016

Undisclosed

$595.0M

Undisclosed

Get a free BioCentury trial today